Validation of an Allergic Rhinitis Control Test in Teenagers

NCT02818153 | Unknown DMC

• 1 other identifier: 9614
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Allergic rhinitis is a common condition that affects adults as well as children and adolescents, often with impaired quality of life. Patients often report a poor level of satisfaction with the effectiveness of their treatment and are always looking for more drug combinations to improve their symptom. Several tools exist for assessing control of allergic rhinitis, but none has been validated in adolescents or in children. A study conducted in 2008, resulted in the validation of a self-administered control test of allergic rhinitsis (ARCT) in patients from 12 years of age. However, this study included only 67 adolescents aged 12 to 17 years old and lacked power. In this new study,the investigators propose, following exactly the same procedure as the pilot study of 2008, to confirme the validation of unmodified Adult questionnaire in adolescents 12 to 17 years inclusive.

Conditions

Allergic Rhinitis

Keywords

Allergic rhinitis

Outcome Measures

Primary Outcomes (1)

• Score of the allergic rhinitis control self questionnaire in teenagers from 12 to 17 years old.

  15 days

Study Arms (1)

questionnaire for allergic rhinitis control

EXPERIMENTAL

Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days

Other: Self questionnaire for allergic rhinitis control

Interventions

Self questionnaire for allergic rhinitis control OTHER

questionnaire for allergic rhinitis control

Eligibility Criteria

• Age: 12 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Patients aged 12 to 17 years old, consulting a practitioner for an allergic rhinitis
• parents formulated their study participation agreement by signing the consent form.

You may not qualify if:

• Patients that are already treated for the actual episode of allergic rhinitis and are satisfied of the treatement.

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

University hospital of Montpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

Rhinitis, Allergic

Condition Hierarchy (Ancestors)

Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Central Study Contacts

Pascal Demoly, Professor

CONTACT

+334 67 33 61 27; pascal.demoly@inserm.fr

Anca Chiriac, MD

CONTACT

a-chiriac@chu-montpellier.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 27, 2016
• First Posted: June 29, 2016
• Study Start: June 1, 2016
• Primary Completion: September 1, 2016
• Study Completion: June 1, 2017
• Last Updated: June 29, 2016

Record last verified: 2016-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)